Contact

info@syndevrx.com

1 Broadway # 14, Cambridge, MA 02142

SynDevRx is developing new therapies to improve the future of treatment for:

  • Cancers exacerbated by metabolic dysfunction (i.e. metabo-oncology)

  • Other cancer types (e.g. NSCLC)

  • Other conditions associated with metabolic dysfunction (e.g. T2D, NASH)

Please see below for information on SynDevRx-sponsored clinical trials.

Latest Clinical Trials Updates

Phase 1

A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid Tumors

  • This is a Phase 1 dose escalation to assess the safety, tolerability and maximum tolerated dose of subcutaneous administered SDX-7320 in patients with advanced refractory or late-stage solid tumors.

Status: Recruiting

Trial Details

Phase 1b

A Phase 1b Study of SDX-7320 in Combination with Approved Anti-Cancer Agents to Assess Safety in Patients with Metastatic Breast Cancer

  • This is a multicenter Phase 1b study to assess the safety, tolerability and efficacy of subcutaneously administered SDX-7320 in combination with the standard dose and schedule of approved anti-cancer treatments in postmenopausal women with advanced HR+/HER2- metastatic breast cancer and suspected metabolic dysfunction who have progressed after an initial treatment regimen of hormone therapy with or without a targeted therapy.
  • Other selected, advanced, metabolically-sensitive solid tumor types will be considered for separate treatment arms in both men and women.

Status: Planned for Q3 2018